NZ700833A - Methods of producing anamorelin hydrochloride having controlled chloride content - Google Patents

Methods of producing anamorelin hydrochloride having controlled chloride content

Info

Publication number
NZ700833A
NZ700833A NZ700833A NZ70083313A NZ700833A NZ 700833 A NZ700833 A NZ 700833A NZ 700833 A NZ700833 A NZ 700833A NZ 70083313 A NZ70083313 A NZ 70083313A NZ 700833 A NZ700833 A NZ 700833A
Authority
NZ
New Zealand
Prior art keywords
chloride content
methods
controlled chloride
anamorelin hydrochloride
producing
Prior art date
Application number
NZ700833A
Other languages
English (en)
Inventor
Rubio Silvina Garcia
Shin-Itsu Kuwabe
Takehiko Yanagimachi
Hideyuki Yoshiyama
Groot Eleanor De
Peter Manini
Seemon Pines
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48225135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ700833(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of NZ700833A publication Critical patent/NZ700833A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NZ700833A 2012-04-20 2013-04-18 Methods of producing anamorelin hydrochloride having controlled chloride content NZ700833A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636108P 2012-04-20 2012-04-20
PCT/US2013/037159 WO2013158874A1 (en) 2012-04-20 2013-04-18 Methods of producing anamorelin hydrochloride having controlled chloride content

Publications (1)

Publication Number Publication Date
NZ700833A true NZ700833A (en) 2016-01-29

Family

ID=48225135

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ700833A NZ700833A (en) 2012-04-20 2013-04-18 Methods of producing anamorelin hydrochloride having controlled chloride content

Country Status (47)

Country Link
US (8) US20140018391A1 (enExample)
EP (3) EP3517532B1 (enExample)
JP (3) JP6109925B2 (enExample)
KR (2) KR101972998B1 (enExample)
CN (3) CN110041304A (enExample)
AP (1) AP2014008013A0 (enExample)
AR (1) AR090725A1 (enExample)
AU (1) AU2013249197B2 (enExample)
BR (1) BR112014025972A8 (enExample)
CA (2) CA2869893C (enExample)
CL (1) CL2014002817A1 (enExample)
CO (1) CO7131356A2 (enExample)
CR (1) CR20140530A (enExample)
CY (1) CY1120276T1 (enExample)
DK (2) DK2838892T3 (enExample)
DO (1) DOP2014000235A (enExample)
EA (1) EA031581B1 (enExample)
EC (1) ECSP14027739A (enExample)
ES (2) ES2658862T3 (enExample)
GE (1) GEP20186902B (enExample)
HK (1) HK1248694A1 (enExample)
HR (1) HRP20180316T1 (enExample)
HU (2) HUE035697T2 (enExample)
IL (1) IL235064B (enExample)
JO (1) JO3353B1 (enExample)
LT (1) LT2838892T (enExample)
MA (1) MA37524B1 (enExample)
MD (1) MD4615C1 (enExample)
ME (1) ME02966B (enExample)
MX (1) MX354793B (enExample)
MY (1) MY170068A (enExample)
NI (1) NI201400124A (enExample)
NO (1) NO2877697T3 (enExample)
NZ (1) NZ700833A (enExample)
PE (1) PE20150084A1 (enExample)
PH (1) PH12014502351B1 (enExample)
PL (2) PL3290410T3 (enExample)
PT (2) PT2838892T (enExample)
RS (1) RS56869B1 (enExample)
SG (2) SG11201406478XA (enExample)
SI (2) SI3290410T1 (enExample)
TN (1) TN2014000421A1 (enExample)
TW (2) TWI589572B (enExample)
UA (1) UA116207C2 (enExample)
UY (1) UY34753A (enExample)
WO (1) WO2013158874A1 (enExample)
ZA (1) ZA201408508B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
CN113577074A (zh) * 2014-09-04 2021-11-02 赫尔森保健股份公司 基于阿拉莫林的药物治疗
CR20180023A (es) 2015-07-24 2018-03-20 Newlink Genetics Corp Sales y profármacos de 1-metil-d-triptofano
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
KR20220054244A (ko) 2019-08-30 2022-05-02 헬신 헬스케어 에스아 개선된 안정성을 갖는 아나모렐린 정제의 제조 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
WO2005030698A1 (en) * 2003-09-26 2005-04-07 Ranbaxy Laboratories Limited Process for the preparation of voglibose
EP2298760B1 (en) 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
KR20090112720A (ko) * 2007-02-13 2009-10-28 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

Also Published As

Publication number Publication date
SI3290410T1 (sl) 2020-11-30
JP6109925B2 (ja) 2017-04-05
EA031581B1 (ru) 2019-01-31
BR112014025972A2 (pt) 2017-06-27
US9956261B2 (en) 2018-05-01
UY34753A (es) 2013-11-29
MX2014012178A (es) 2015-08-05
AU2013249197A1 (en) 2014-10-30
MD4615C1 (ro) 2019-08-31
TW201722928A (zh) 2017-07-01
CY1120276T1 (el) 2019-07-10
DOP2014000235A (es) 2015-01-31
JO3353B1 (ar) 2019-03-13
CA2869893C (en) 2019-03-05
US20190000914A1 (en) 2019-01-03
HK1248694A1 (en) 2018-10-19
WO2013158874A1 (en) 2013-10-24
EP2838892B1 (en) 2017-12-06
CN110041304A (zh) 2019-07-23
AU2013249197B2 (en) 2017-04-06
KR101972998B1 (ko) 2019-04-29
ME02966B (me) 2018-07-20
PH12014502351A1 (en) 2015-01-12
US9403867B2 (en) 2016-08-02
TWI677494B (zh) 2019-11-21
ECSP14027739A (es) 2015-12-31
EP3290410B1 (en) 2020-07-01
HUE050865T2 (hu) 2021-01-28
PL3290410T3 (pl) 2021-01-11
US20160229889A1 (en) 2016-08-11
JP2015514779A (ja) 2015-05-21
PH12014502351B1 (en) 2015-01-12
MD4615B1 (ro) 2019-01-31
ZA201408508B (en) 2020-01-29
PT2838892T (pt) 2018-02-28
US10300105B2 (en) 2019-05-28
BR112014025972A8 (pt) 2021-06-22
TW201348224A (zh) 2013-12-01
SG10201608488RA (en) 2016-12-29
KR20150013115A (ko) 2015-02-04
HUE035697T2 (en) 2018-05-28
UA116207C2 (uk) 2018-02-26
NO2877697T3 (enExample) 2018-10-13
EP3517532A1 (en) 2019-07-31
ES2658862T3 (es) 2018-03-12
EP3517532B1 (en) 2021-10-13
HRP20180316T1 (hr) 2018-04-06
PL2838892T3 (pl) 2018-05-30
US10576122B2 (en) 2020-03-03
US20150072934A1 (en) 2015-03-12
CA2869893A1 (en) 2013-10-24
SI2838892T1 (en) 2018-05-31
US9981002B2 (en) 2018-05-29
US10905737B2 (en) 2021-02-02
AP2014008013A0 (en) 2014-10-31
CO7131356A2 (es) 2014-12-01
ES2820354T3 (es) 2021-04-20
DK2838892T3 (en) 2018-03-12
CN110041398A (zh) 2019-07-23
CA3031652C (en) 2020-10-27
EA201401151A1 (ru) 2015-06-30
EP3290410A1 (en) 2018-03-07
MD20140122A2 (ro) 2015-05-31
PE20150084A1 (es) 2015-01-23
CN103857669B (zh) 2019-06-28
US20160235804A1 (en) 2016-08-18
KR102141323B1 (ko) 2020-08-05
US20200276259A1 (en) 2020-09-03
JP6616853B2 (ja) 2019-12-04
MX354793B (es) 2018-03-21
RS56869B1 (sr) 2018-04-30
HK1202863A1 (en) 2015-10-09
IL235064A0 (en) 2014-12-31
JP2018076375A (ja) 2018-05-17
PT3517532T (pt) 2021-11-08
CN103857669A (zh) 2014-06-11
JP2017101082A (ja) 2017-06-08
SG11201406478XA (en) 2014-11-27
MY170068A (en) 2019-07-03
IL235064B (en) 2019-09-26
NI201400124A (es) 2015-09-21
CL2014002817A1 (es) 2015-08-14
AR090725A1 (es) 2014-12-03
TN2014000421A1 (en) 2016-03-30
US9872883B2 (en) 2018-01-23
KR20190044697A (ko) 2019-04-30
US20140018391A1 (en) 2014-01-16
CR20140530A (es) 2015-03-25
US20190231843A1 (en) 2019-08-01
MA37524A1 (fr) 2016-06-30
DK3517532T3 (da) 2022-01-03
US20160237115A1 (en) 2016-08-18
CA3031652A1 (en) 2013-10-24
TWI589572B (zh) 2017-07-01
GEP20186902B (en) 2018-10-25
MA37524B1 (fr) 2017-04-28
EP2838892A1 (en) 2015-02-25
LT2838892T (lt) 2018-03-12
JP6284665B2 (ja) 2018-02-28

Similar Documents

Publication Publication Date Title
PH12013501821A1 (en) Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
PH12014501595A1 (en) Substituted annulated pyrimidines and triazines, and use thereof
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
IN2014DN10386A (enExample)
PT2763982T (pt) Benzimidazois substituídos para utilização como inibidores da bub1 quinase no tratamento de doenças hiperploriferativas
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
UA111186C2 (uk) Способи та композиції для одержання норибогаїну з воакангіну
PL2922893T3 (pl) Kompozycje utwardzane wilgocią, sposób ich wytwarzania i ich zastosowania
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
WO2013164839A3 (en) Amorphous form of apixaban, process of preparation and compositions thereof
PH12014502351A1 (en) Methods of producing anamorelin hydrochloride having controlled chloride content
IN2013MU03641A (enExample)
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2015016603A (es) Composiciones de corticosteroides.
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
IN2013MU02777A (enExample)
MY168958A (en) Intermediates and processes for preparing compounds
MX2012014969A (es) Composiciones farmaceuticas estables de amlodipina con telmisartan.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2018 BY ANAQUA SERVICES

Effective date: 20170321

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2019 BY ANAQUA SERVICES

Effective date: 20180320

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2020 BY ANAQUA SERVICES

Effective date: 20190321

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2021 BY ANAQUA SERVICES

Effective date: 20200318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2022 BY ANAQUA SERVICES

Effective date: 20210323

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2023 BY ANAQUA SERVICES

Effective date: 20220324

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2024 BY ANAQUA SERVICES

Effective date: 20230322

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2025 BY ANAQUA SERVICES

Effective date: 20240320

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2026 BY ANAQUA SERVICES

Effective date: 20250319